Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Liabilities (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Total Liabilities for 11 consecutive years, with $170.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 46.49% to $170.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $170.7 million, a 46.49% decrease, with the full-year FY2025 number at $170.7 million, down 46.49% from a year prior.
  • Total Liabilities was $170.7 million for Q4 2025 at Intellia Therapeutics, down from $176.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $319.1 million in Q4 2024 to a low of $170.7 million in Q4 2025.
  • A 5-year average of $223.3 million and a median of $222.0 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: soared 155.28% in 2021, then tumbled 46.49% in 2025.
  • Intellia Therapeutics' Total Liabilities stood at $254.2 million in 2021, then rose by 11.92% to $284.5 million in 2022, then decreased by 11.85% to $250.8 million in 2023, then grew by 27.21% to $319.1 million in 2024, then crashed by 46.49% to $170.7 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Total Liabilities are $170.7 million (Q4 2025), $176.9 million (Q3 2025), and $183.6 million (Q2 2025).